NCT00000977View on ClinicalTrials.gov

Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity

PHASE1CompletedINTERVENTIONAL

Enrollment

52

Participants

Timeline

Start Date

Not specified

Study Completion Date

May 31, 1993

Conditions

HIV Infections

Interventions

BIOLOGICAL

gp160 Vaccine (MicroGeneSys)

Trial Locations (2)

10016

NY Univ. HIV/AIDS CRS, New York

94305

Stanford CRS, Palo Alto

All Listed Sponsors

collaborator

Protein Sciences Corporation

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH